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ABSTRACT
We have used metadynamics to investigate the
mechanism of noncovalent dissociation from DNA
by two representatives of alkylating and noncovalent
minor groove (MG) binders. The compounds are
anthramycin in its anhydrous form (IMI) and distamy-
cin A (DST), which differ in mode of binding, size,
flexibility and net charge. This choice enables to
evaluate the influence of such factors on the
mechanism of dissociation. Dissociation of IMI
requires an activation free energy of ~12 kcal/mol
and occurs via local widening of the MG and loss
of contacts between the drug and one DNA
strand, along with the insertion of waters in between.
The detachment of DST occurs at a larger free
energy cost, ~16.5 or ~18 kcal/mol depending on
the binding mode. These values compare well with
that of 16.6 kcal/mol extracted from stopped-flow
experiments. In contrast to IMI, an intermediate is
found in which the ligand is anchored to the DNA
through its amidinium tail. From this conformation,
binding and unbinding occur almost at the same
rate. Comparison between DST and with kinetic
models for the dissociation of Hoechst 33258 from
DNA uncovers common characteristics across dif-
ferent classes of noncovalent MG ligands.
INTRODUCTION
In the last decades, many complexes between DNA and
drugs targeting the minor groove (MG) have been exten-
sively studied using experimental biophysical techniques
as well as molecular simulations (1–13). In contrast, the
structural determinants and relative energies playing a role
in molecular recognition have been poorly characterized
(14–20), despite their relevance for rational drug design
(21,22). Recognition is known to be a complex process
that may involve several steps before formation of the
most stable adduct: both noncovalent (17,19,23) and
covalent (16,24) binders may exploit mechanisms like
one-dimensional sliding within the MG and translocation
among diﬀerent sites (involving binding and dissociation)
(10,25–28). In particular, the importance of dissociation
for the selectivity and the aﬃnity of diﬀerent MG binders
has been pointed out by several experimental studies
(17,18,23,29,30). Such an experimental eﬀort has not
been accompanied yet by a thorough theoretical investi-
gation, which would be certainly fundamental to address
the mechanism and the energetics of detachment at a
molecular level.
Dissociation of a ligand from DNA generally occurs
on a time scale not reachable by standard molecular
dynamics (MD) simulations; thus, enhanced-sampling
methods are needed to perform such an investigation.
Fortunately, in the last years the development of novel
methods to accelerate rare events (31), along with the
increased reliability of force ﬁelds (32–36) and simulation
protocols (37,38), enabled nonequilibrium dynamics of
complex biological systems to be characterized (39–43).
Among them, metadynamics (44) has been largely used
to identify mechanisms of and to extract free energies
associated with biologically relevant processes (45–47).
In particular, the technique has been successfully applied
to get insights on aspects of the molecular recognition
of proteins by small ligands (48,49), while, to the best of
our knowledge, it has never been exploited to investigate
the dynamics of ligand/DNA systems.
In this work, the ﬁrst computational study is presented
on the dissociation of MG binders from DNA, as one of
the key events of the translocation among diﬀerent sites
[notice that the binding mechanism of the intercalating
agent daunomycin has recently been described (20)].
Within the framework of classical MD, we have used
metadynamics to explore the inﬂuence of size, ﬂexibility
and charge of the compounds on the detachment mech-
anism. The comparison has been performed on two rep-
resentatives of noncovalent and covalent MG binders
which diﬀer in the properties listed above, considering
their noncovalent adducts with DNA duplexes. The
prototype of noncovalent binders is distamycin A (50)
(hereafter DST, Scheme 1), which is positively charged,
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quite ﬂexible and highly selective towards AT-rich tracts
(51,52), due to H-bonding between its amide nitrogens
and N3(A) and/or O2(T) of DNA (22,53–55). The alkylat-
ing agent is anthramycin (56,57), here considered in its
most reactive anhydrous form (10,58) (hereafter IMI,
Scheme 1). In contrast to DST, anthramycin is neutral,
rather rigid, and manifests only a modest preference
towards PuGPu triplets (59), the asterisk indicating the
alkylated guanine. Both compounds have shown to exert
an antitumoral action by interfering with transcription
(6,54,60–62) and replication (57,63,64) processes, and
their derivatives are currently undergoing clinical trials
as anticancer drugs (65–72).
Besides the general motivation outlined above, addi-
tional reasons have guided our choice of the compounds.
First, structural information of the drug/DNA noncova-
lent complexes is available: the X-ray structure of the
complexes between DST and duplexes d[GGCCAAT
TGG]2 and d[CGCAAATTTGCG]2 has been solved
(51,52), whilst that of a noncovalent complex between
IMI and the 14-mer d[50-CAACGTTGGCCAAC-30]2
has been recently modeled by the authors (10,28), starting
from the experimental structure of the covalent complex
(56). Second, the dissociation rate constant of DST from
the 10-mer d[GCGATTAGCG]2 (which is the same
duplex used in our simulations) has been derived from
stopped-ﬂow experiments (19), enabling the direct com-
parison between calculated and experimental activation
free-energy barriers of the process. Since the duplex
d[GCGATTAGCG]2 is not palindromic, the two possible
binding orientations of DST have been considered to
pinpoint their possible inﬂuence on the escaping process.
Our calculations provide a microscopic picture of
the dissociation of the two molecules, along with the
free energy surfaces (FESs) associated with the process.
To identify relevant conformations and to estimate more
accurately the associated free energies, the lowest free-
energy path (LFEP) (73), which is equivalent to an
intrinsic reaction coordinate (IRC) and gives the
minimum cost path of detachment, has been evaluated
on the FESs. Such an approach has been successfully
used in previous works on biochemical relevant pro-
cesses (74–76).
Our simulations pinpoint relevant similarities and dif-
ferences between the dissociation mechanisms of the two
compounds. Additionally, our results are in good agree-
ment with the available kinetic data extracted from
stopped-ﬂow experiments for DST (19), furnishing molec-
ular-level details on the dissociation that are not available
to experiment. Finally, the comparison of the mechanism
we found for DST with a kinetic model proposed for the
binding/unbinding of the dye Hoechst 33258 suggests the
existence of very similar recognition routes followed by
diﬀerent classes of MG binders.
MATERIALS AND METHODS
Systems
The DSTd[50-GCGATTAGCG-30]2 (in bold the binding
sequence) complex was built by taking the ligand from the
X-ray structure of its adduct with the duplex
d[GGCCAATTGG]2 [PDB code 1JTL (51)], and by build-
ing the 10-mer using the nucgen module of AMBER
(77,78). Since the DNA sequence is not palindromic, two
nonequivalent orientations of the ligand inside the MG
were considered. In one (hereafter called DSTDNA),
the amidinium group of DST is in contact with the tract
d[A7G8]2; in the second pose (hereafter DSTDNA0), the
same group is close to the tract d[G3A4]2. Both orienta-
tions resulted in stable adducts after 6 ns of MD simula-
tions (vide infra). The initial structure of the noncovalent
complex IMId[50-CAACGTTGGCCAAC-30]2 was
extracted from a previous MD simulation (10). There
the adduct was built starting from the X-ray structure of
the covalent complex between anthramycin and the 10-
mer d[50-CCAACGTTGG-30]2 [PDB code 274D (56)],
the asterisk labeling the covalently modiﬁed base. The
binding sequence assumed as starting conﬁguration in
the present work is adjacent to that in the covalent com-
plex, and has been shown to be a more stable free-energy
minimum (28). In addition, 6 ns long simulations were
performed of the free-standing duplexes d[50-GC
GATTAGCG-30]2 and d[50-CAACGTTGGCCAAC-30]2,
as well of the ligands IMI and DST, in solution.
Parameterization
The PARMBSC0 reﬁnement of the parm99 force ﬁeld
(32,33) was used for the parameterization of the oligonu-
cleotide moieties, while force ﬁeld parameters for IMI
were taken from ref. (10). Parameters for DST were cal-
culated following the standard AMBER procedure, using
the gaﬀ force ﬁeld (79), except for the charges, which were
evaluated according to the RESP approach: the ligand
was ﬁrstly optimized at the HF/6-31G(d) level up to a
convergence in energy of 105AU using the Gaussian03
(80,81) package. The CPCM (82) implicit solvent model
was employed to mimic the presence of the solvent,
in order to avoid formation of intramolecular H-bonds
due to the in vacuo conditions. A second restrained
optimization was then performed at the same level of
theory but in vacuo, and the electrostatic potential map
generated by the molecule was then calculated [this pro-
tocol ensure to extract atomic charges consistent with the
AMBER force ﬁeld (83)]. From the potential the atomic
RESP (84) charges were derived using the antechamber
module of the AMBER package (78).
Scheme 1.
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MD calculations
The neutrality of the systems was achieved through the
addition of sodium counter-ions (18 in DSTDNA and
in the corresponding simulation of the free-standing
duplex; 22 in IMIDNA and in the corresponding simula-
tion of the free-standing duplex; 1 in the simulation of
the free-standing DST) modeled with the AMBER-
adapted Aqvist (85) potential. Resulting structures were
solvated within a monoclinic box containing 10 246
(DSTDNA), 9827 (DSTDNA0), 6719 (d[50-GCGATT
AGCG-30]2), 13 611 (IMIDNA), 8723 (d[50-CAACGT
TGGCCAAC-30]2), 3278 (IMI) and 4097 (DST) water
molecules, described by the TIP3P (86) potential.
Periodic boundary conditions were applied. The initial
sizes of the boxes were 60 84 69 A˚3, 57 80 69 A˚3,
57 56 69 A˚3, 75 80 72 A˚3, 59 80 62 A˚3,
47 47 48 A˚3 and 52 52 52 A˚3 in DSTDNA,
DSTDNA0, d[50-GCGATTAGCG-30]2, IMIDNA, d[50-
CAACGTTGGCCAAC-30]2, IMI and DST respectively.
This choice ensures that the minimum distance between
solute images is >25 A˚ during the whole dissociation
process.
Electrostatic interactions were treated using the particle
mesh Ewald (37) (PME) algorithm with a real space cut-
oﬀ of 10 A˚, the same as for van der Waals interactions.
The pair list was updated every 10 steps, and Lincs con-
straints (87) were applied to all bonds involving hydrogen
atoms, permitting a time step of 2 fs. NPT conditions
were achieved by coupling the systems to the Nose´–
Hoover (88,89) thermostat (=1ps) and the Andersen–
Parrinello–Rahman (90,91) barostat (=1ps).
The systems were equilibrated using the following
computational procedure: (i) structural optimization
of the solvent, using the conjugate gradient algorithm;
(ii) energy minimization of the entire system, using the
same convergence criteria as in (i); (iii) linear heating of
the system up to 300K in 100 ps, while imposing harmonic
restraints on the solute (k=5kcal/A˚2); (iv) 5 ns of con-
stant temperature–pressure (T=300K, P=1atm). This
temperature, although lower than that of the human body,
is virtually the same at which the available kinetic mea-
surements in vitro have been performed, i.e. 298K (19).
Starting structures for metadynamics were taken from
the last nanosecond of MD, selecting those with the lowest
RMSD with respect to the average structure of the solute
(also calculated within the last nanosecond). The MG
width of DNA was deﬁned by taking the distances
between sugar C40 atoms, and calculated with the program
Curves (92–94). All simulations were carried out using a
modiﬁed version of the GROMACS (95–97) package
implemented with metadynamics (46).
Metadynamics
Dissociation of the ligands was investigated by metady-
namics (44), a method to compute free energies and to
accelerate rare events. The algorithm is based on a dimen-
sional reduction: a set of collective variables (CVs)
si (i=1,. . .,NCVs), function of the coordinates of the
system x={x1, x2,. . ., xN}, where N is the number of par-
ticles, is evolved with a standard MD supplemented by a
history-dependent potential, discouraging the system from
visiting previously sampled conformations. In the standard
implementation the history-dependent potential is built-up
by Gaussians of NCVs-th dimension, height w and widths
dsi (i=1,. . .,NCVs), deposed at time intervals G along the
CVs trajectory. In the limit of a long metadynamics run,
the sum of these penalty terms tends to compensate exactly
the underlying FES in the reduced space, permitting a
reconstruction of the FES explored up to time t (98).
The CVs used here to describe IMI and DST dissocia-
tion are:
(1) The distance dCMs between the centers of mass of
the ligand and of the DNA tracts d[GTTGG]2 and
d[CATTAC]2 (for IMI and DST, respectively). A simi-
lar choice of CVs has been applied, e.g. in ref. (49).
(2) The number of hydrophobic contacts nhph between
nonpolar carbons on the ligand and on the bases
covered by the ligand in the starting structure, mod-
eled as a coordination number:
nhph ¼
X
ij
1 rij=r0
 a
1 rij=r0
 b 1
The parameters a and b have values of 6 and 12,
respectively, while r0=6 A˚ accounts for the typical
carbon–carbon distance (4/4.5 A˚) and the thermal
motions’ amplitude (1.5/2 A˚). A similar CV has
been used in refs (48, 99).
(3) The number nhb of H-bonds between the ligand and
the bases that it covers in the starting structure,
described also by Equation (1) with a=8, b=12
and r0=2.5 A˚. A similar CV has been chosen in
refs (45, 46).
The choice of the Gaussian parameters is crucial. Here,
the height w has been chosen following both theoretical
suggestions and previous experience on similar problems
(47,49,98), to be 0.024 kcal/mol (0.1 kj/mol) and
0.072 kcal/mol (0.3 kj/mol) for IMI and DST, respec-
tively. Concerning the widths of the Gaussians, as a rule
of thumb they should be 1/3 of the typical ﬂuctuations of
the CV during a free MD (49); following this rule, we have
chosen dsCMs=0.5 A˚, dshph=6 and dshb=1 in the case
of IMI, dsCMs=0.5 A˚, dshph=6 and dshb=3 for DST.
The time interval between two successive Gaussian deposi-
tions was set to 0.5 ps in all the simulations.
FESs for IMIDNA and DSTDNA were calcu-
lated as a function of (dCMs, nhph) and (dCMs, nhb); in
addition, simulations were performed in which the
three CVs were kept active. In every metadynamics run,
the dissociation event was observed after a few nano-
seconds (see Supplementary Table S1). In the case of
DSTDNA0, we initially used dCMs and nhb as active
variables: as we obtained dissociation mechanism and
a free-energy landscape similar to those found in
DSTDNA (vide infra), no additional simulations were
performed. The activation free energies associated with
the detachments were extracted by stopping the sum-
mation over Gaussians just after the complete detach-
ment of the drug (49). Notice that no estimation of the
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binding free energy has been done in the present work.
This would require (even in the presence of additional
restraints) a more extensive simulation, and goes beyond
the scope of the present article. It is also worth pointing
out that the bias introduced by metadynamics has been
shown to unaﬀect a proper reconstruction of the entropy,
which converges as fast as the free energy and has the
same accuracy (100).
For the sake of clarity, we show here only the free-
energy proﬁles as a function of dCMs and nhph in case
of IMIDNA and as a function of dCMs and nhb in case
of DSTDNA. The average error " associated with these
free-energy proﬁles was evaluated as in ref. (48) after
rescaling each CV to the size of the free energy well
S in the corresponding direction (98). Here, we used
SCMs 0.2 nm, Shph 40 in the case of IMIDNA,
SCMs 0.3 nm, Shb 20 in the case of DSTDNA (and
DSTDNA0), which gave " of 1.6 and 2.2 kcal/mol,
respectively.
LFEPs and structural/energetical analyses
The LFEP, which is the equivalent of the IRC at ﬁnite
temperature, has been calculated on the FESs following
the methodology of ref. (73). It has been shown that rele-
vant minima, intermediates and transition states for the
process under study can be identiﬁed along this path
(74–76). To extract structural and energetic information
on the process, a cluster analysis using the algorithm
described in ref. (101) with a cutoﬀ of 1.5 A˚ has been
performed on the ensemble of conﬁgurations correspond-
ing to relevant points along the LFEP. For each ensemble
of structures, a dominant cluster has been found which is
larger in size at least one order of magnitude with respect
to the others. For this reason, the structural parameters
and the contributions to the free energy were calculated
by averaging over each principal cluster only. The free
energy along the LFEP has been dissected into the follow-
ing sources: (i) van der Waals and Coulomb energies,
evaluated using the terms in the AMBER force ﬁeld;
(ii) entropy and free energy of hydration, evaluated as
Cpln(T/386) kcal/mol/T and Cp(T 295) kcal/mol
(5,102). The heat capacity changes Cp are calculated
as Cp= 0.32Anp 0.14Ap cal/mol/K, where Anp
and Ap are the variations in the hydrophobic (non-
polar) and hydrophilic (polar) surface areas,
respectively (102).
It is worthy to point out that while calculated free energies
are suﬃciently accurate to enable comparison with experi-
mental data, contributing sources have usually larger SDs,
and will be used here only for qualitative comparison.
RESULTS
In this section, we analyze the mechanism of dissociation
of IMI and DST from their respective DNA duplexes.
In addition, we report the associated free energy barriers,
as well as the changes in interaction energy, hydration and
structure of the complexes. For DST, we considered both
the orientations of the ligand within the MG (systems
DSTDNA and DSTDNA0, see Supplementary
Figure S1). Because of the similar mechanism and ener-
getics of detachment found in the two systems, here we
present results only for DSTDNA. The proﬁle and the
relevant diﬀerences in free energies associated with
the detachment of DST in DSTDNA0 are collected in
the Supplementary Material (Figure S2), along with
a movie of the process (see ‘movie_DST_ﬂip.mpg’ in the
Supplementary Material). A small summary of our ﬁnd-
ings on DSTDNA0 is reported at the end of this section.
The free-energy surfaces were calculated as a function
of variety of collective variables (or reaction coordinates),
using the metadynamics method (44). Here, we report the
free-energy surfaces G(dCMs, nhph) for IMIDNA and
G(dCMs, nhb) for DSTDNA, where dCMs is the distance
between the centers of mass of the ligand and of the DNA
tracts it covers, nhph the number of hydrophobic contacts,
and nhb the number of hydrogen bonds (the latter have
been modeled through a coordination number, see section
‘‘Materials and Methods’’). A virtually identical dissocia-
tion mechanism resulted from additional metadynamics
simulations, in which diﬀerent combinations of CVs
were purposely selected (see section ‘‘Choice of the CVs’’
and the Movies in the Supplementary Material).
Before presenting in detail our main results, we would
like to remark the following general points:
 Since we were interested in estimating the free-energy
barriers of dissociation, simulations have been stopped
once the ligand is completely detached from the DNA
duplex. Thus, in conformations labeled as ‘Out’ in
Figures 1 and 2, referring to the unbound state, the
duplexes and the ligands do not have necessarily the
structure of the correspondingly equilibrated free-
standing systems (for example, residual interface
waters could be present that have not yet relaxed).
To compare the energetics of the systems (and, in par-
ticular the structural changes of the duplexes along the
process) with respect to an equilibrated reference state,
we have performed additional simulations of duplexes
and ligands in solution. These simulations will be
labeled as ‘Free’ in the following, the meaning being
clear from the context (e.g. the free energy of hydra-
tion of IMIDNA will be referred to the sum of those
of IMI and DNA, while the structural distortions of
the DNAs along the LFEP will be referred to the
values extracted from the simulation of the free-stand-
ing duplexes).
 We have followed the conformational changes under-
gone by the duplexes and the ligands upon disso-
ciation. In particular, we have analyzed bending,
variations in the MG width and changes in the
interbase-pair parameters twist, roll and tilt of the
duplex. Although the DNA is undergoing signiﬁcant
structural changes in the process, the distortions turn
out to be quite localized, and the duplexes always stay
closer to B- than A-DNA form, without featuring
overall bending. For this reason, we refer the reader
interested in a discussion of local conformational
changes and of their connection to kinks in the
helical axis and/or changes in the MG width, to the
Supplementary Information (Figures S5–S8).
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We start with the description of the dissociation of IMI
from DNA. When not speciﬁed, all the values and the
comparisons are referred to the absolute minimum
(labeled ‘Min1’) of each system.
IMI
The initial structural model has been taken from the
ﬁnal conﬁguration of a previous MD simulation (10)
of the adduct IMId[50-CAACGTTGGCCAAC-30]2.
In this conﬁguration, the binding site of IMI, located in
d[50-TTG-30]2, does not coincide with its alkylation site
d[50-TGG-30]2: indeed, this structure corresponds to that
found in ref. (10) after sliding of IMI along the MG, and it
has been shown to be a minimum along the sliding path-
way (28).
The FES G(dCMs nhph) corresponding to the dissociation
of IMI, the associated LFEP and the relevant
Figure 2. Free-energy surface G(dCMs nhb) associated with the detachment of DST from DNA. Labeling of nucleobases is indicated in the ‘Min 1’
conﬁguration. See Figure 1 for further details.
Figure 1. Free-energy surface G(dCMs nhph) associated with the dissociation of IMI from DNA. A LFEP (red line) is also shown connecting relevant
minima and transition states (whose representative structures are also shown by green ﬁlled circles). Isosurfaces are drawn one per 2 kcal/mol. Labeling of
nuclebases is indicated in the ‘Out’ conﬁguration.
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conformations of the complex are collected in Figure 1.
There are two virtually isothermic global minima, sepa-
rated by a small barrier of 3 kcal/mol (Table 1). In the
ﬁrst (Min1, the absolute minimum), located at
dCM 0.68 nm, nhph 199, the drug is bound at the tract
d[50-TTG-30]2 and stabilized by van der Waals and
Coulomb interactions (Table 2); on average, a single H-
bond is formed, involving bases G7, A21 and the hydroxyl
group and N10 of IMI.
Min2 diﬀers from Min1 only for a local deformation of
the DNA duplex (the MG widens by 1 A˚ in the tract
d[50-TGG-30]2, Figure 3a) rather than for a diﬀerent posi-
tion of the drug into the MG (Supplementary Figure S3).
Consistently, these states feature very similar drug/DNA
interaction strengths and hydration properties (Table 2).
The two minima are separated by a transition state TS1-2
of 3 kcal/mol; in the conformation associated with
TS1-2, the whole MG width proﬁle virtually overlaps to
that found in Min2 (Figure 3a), suggesting that this open-
ing is related to the transition from Min1.
Detachment of the drug starts at TS1-3, which
corresponds to a free energy of 7 kcal/mol. Here, the
tract d[50-TTG-30]2 opens and a few water molecules
intercalate between IMI and strand #1 (which contains
the alkylating guanine, see Figure 1 and Supplementary
Figure S2). Accordingly: (i) the free energy of hydration
Ghyd, calculated relatively to the unbound conﬁgura-
tions, increases (Table 2); (ii) drug/DNA van der Waals
interactions weaken, in particular those involving strand
#1 (Figure 4a).
The next point along the LFEP after TS1-3 is the meta-
stable minimum Min3, associated with a G of 6 kcal/
mol: more waters enter the region between the drug and
strand #1, so that the ligand lays now on strand #2
(Figure S4). The relief of the steric hindrance due to the
DNA backbone permits a slight relaxation of IMI, which
can be quantiﬁed through the values of the dihedral angles
between benzene and pyrrol rings and between the pyrrol
and the CONH2 tail (Dihe1 and Dihe2, respectively in
Supplementary Table S2).
From Min3, dissociation proceeds through the high-
est transition state, TS3-4, found at dCM 1.47 nm,
nhph 35, and corresponding to a Gz of 12 kcal/mol.
In this conformation, the principal axis of the drug is
almost perpendicular to that of the DNA. IMI keeps a
weak contact with the duplex through its hydrophilic
Table 1. Free energies (kcal/mol) associated with relevant conﬁgurations which deﬁne the LFEP in IMIDNA (top) and DSTDNA (bottom,
see also Figures 1 and 2)
IMIDNA Min 1 TS 1-2 TS 1-3 Min 2 Min 3 TS 3-4
dCMs, nhph 0.68, 199 0.61, 186 0.69, 133 0.54, 188 0.86, 117 1.47, 35
G 0.0 3.0 6.7 0.7 5.7 12.3
DSTDNA Min 1 TS 1-2 Min 2 TS 2-3 Min 3 TS 3-4
dCMs, nhb 0.45, 57 0.61, 40 0.69, 40 1.13, 24 1.38, 19 1.84, 5.3
G 0.0 5.4 4.5 17.8 10.2 17.2
Values are calculated with respect to the absolute minimum (Min1).
Table 2. Selected quantities (SD in brackets) calculated for the relevant conformations along the LFEPs of IMIDNA (between IMI and tract
d[50-CGTTGGC-30]2, top) and DSTDNA (between DST and tract d[50-CGATTAGC-30]2, bottom)
IMIDNA Min 1 TS 1-2 TS 1-3 Min 2 Min 3 TS 3-4
Coulomb 8.4 (2.5) 7.3 (2.4) 4.8 (3.0) 7.9 (2.4) 2.9 (2.3) 2.3 (1.3)
Van der Waals2 38.1 (3.4) 37.7 (4.9) 22.2 (3.5) 38.0 (4.3) 19.4 (2.4) 6.2 (2.2)
# H-bonds 0.9 (0.6) 0.7 (0.5) 0.5 (0.8) 0.7 (0.5) 0.2 (0.7) 0.0 (0.2)
TShyd 4.7 (9.8) 4.7 (9.8) 4.7 (9.8) 4.7 (9.1) 2.5 (9.8) 0.2 (9.1)
Ghyd 5.0 (10.5) 5.0 (10.5) 3.4 (10.5) 5.0 (9.7) 2.6 (10.5) 0.2 (9.7)
# H2OIMI 9.0 (1.7) 9.1 (1.6) 11.0 (2.3) 8.8 (1.7) 12.4 (2.2) 13.4 (2.4)
# H2Od[50-CGTTGGC-30 ]2 6.6 (1.3) 6.7 (1.1) 7.2 (1.1) 6.7 (1.2) 8.9 (1.2) 10.6 (1.0)
DSTDNA Min 1 TS 1-2 Min 2 TS 2-3 Min 3 TS 3-4
Coulomb 35.4 (5.3) 20.6 (2.8) 23.5 (5.6) 20.8 (3.7) 13.9 (5.2) 18.2 (1.2)
Van der Waals2 75.3 (4.6) 59.5 (4.5) 56.1 (2.4) 21.1 (4.0) 12.2 (2.3) 0.9 (2.1)
# H-bonds 3.9 (1.0) 1.7 (0.8) 1.7 (0.8) 1.5 (0.7) 1.5 (0.7) 1.0 (0.2)
TShyd 13.1 (9.1) 11.6 (10.6) 9.4 (8.3) 5.3 (11.3) 3.3 (9.8) 0.5 (5.4)
Ghyd 13.9 (9.7) 12.3 (11.3) 9.9 (8.9) 5.8 (12.1) 3.4 (10.5) 0.5 (6.3)
# H2ODST 11.4 (1.9) 16.4 (1.9) 18.0 (1.5) 18.9 (3.2) 19.8 (2.5) 22.3 (3.7)
# H2Od[50-CGATTAGC-30 ]2 5.4 (0.8) 8.9 (1.6) 12.5 (0.7) 10.7 (1.1) 12.5 (1.1) 15.3 (1.3)
The Coulomb and van der Waals energies are reported in Kilocalories per mole (the values of Coulomb and van der Waals interaction energies in
‘Out’ are respectively 0.1 and 0.4 kcal/mol in IMIDNA, and 0.1, 0.1 kcal/mol in DSTDNA). These are very approximate values and they are
reported here only for qualitative comparisons. The hydration entropies (times the temperature) and hydration free energies are calculated as in ref.
(102) and referred to the unbound system (i.e. to the sum of the same quantities extracted from simulations of free-standing duplexes and free ligands
in solution). The number of intermolecular H-bonds and the number of waters within the ﬁrst hydration shells of the ligand and of DNA tracts
d[50-CGTTGGC-30]2 (IMI) or d[50-CGATTAGC-30]2 (DST) are also reported.
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tail, but does not form H-bonds, and its head (A in
Scheme 1) is completely solvated. From this conforma-
tion, the complete dissociation of the ligand takes place
(conformation ‘Out’).
Concerning structural distortions of the duplex along
the detachment route, its RMSDs increases up to >2 A˚
with respect to Min1 (Supplementary Table S2). Despite
this, the RMSD with respect to canonical B-DNA remains
lower than that from A-DNA form. In addition, the
RMSD with respect to the average structure of the free-
standing DNA (‘Free’) is almost constant around 2 A˚
during the process. As found for the structure of IMI,
no evidences of signiﬁcant changes compared to Min1
are present.
Summarizing, dissociation of IMI occurs through the fol-
lowing steps: the drug ﬁrst loses contacts with strand #1,
allowing waters to insert in between (TS1-3, Min3), then it
experiences a complete detachment crossing a transition
state in which its head leaves the MG (TS3-4), while
the tail keeps small residual interactions with the DNA
The eﬀective calculated barrier for the exit of the drug is
12kcal/mol, and no additional stable states are found
along the LFEP apart from the absolute minimum Min1.
DST
The starting complex has been built by manually docking
the ligand, taken from the X-ray structure of the adduct
DSTd[GGCCAATTGG]2, on the 10-mer d[GCGATTA
GCG]2 (see section ‘‘Materials and Methods’’ for details
on the setup of the system). Note that this is the same
duplex used in the stopped-ﬂow experiments of ref. (19)
(see section ‘‘Materials andMethods’’). The FESG(dCMs nhb)
corresponding to ligand dissociation, the LFEP and
the relevant conformations adopted by the complex are
shown in Figure 2. The bound conformation is associated
with a single broad minimum (Min1) centered at dCMs
0.45 nm, nhb 57, in which the drug binding mode is very
similar to that observed in the X-ray structure of ref. (51):
(i) the pyrrol rings A and B (Scheme 1) are slightly rotated
with respect to each other to match the curvature of
the groove. To quantify the distortion, we have deﬁned
the dihedral angles between pyrrol rings A and B (Dihe1
in Scheme 1), B and C (Dihe2) and between the amidinium
tail and ring C (Dihe3). The Dihe1 and Dihe2 have values
of 208, as in the X-ray structure (51), while Dihe3
changes by 1808. However, this change does not aﬀect
the orientation of the diamino group with respect to the
MG, and thus the interaction network (Supplementary
Table S3); (ii) DST inﬂuences asymmetrically the MG
width, wider at the 30 end of strand #1 (Figure 3b), whereas
it does not have an eﬀect on the structural parameters of
the duplex (Supplementary Table S3), as in the X-ray
structure; (iii) approximately four H-bonds on average
are formed between the ligand and the DNA duplex
Figure 4. Interaction energies between the drugs and selected tracts along each DNA strand. The fraction of the total LJ+Coulomb interaction
energy between ligand and strand #2 is also shown as a percentage. (a) IMI with d[50-C4GTTG
GC10-30] (strand #1) and d[50-C18GTTG
GC24-30]
(strand #2). Arrows indicate conﬁgurations where waters enter the region between IMI and strand1 (see also Supplementary Figure S4), weakening
hydrophobic interactions; (b) DST with the tracts d[50-C2GATTAGC9-30] (strand #1) and d[50-G11CTAATCG19-30] (strand #2). In contrast to IMI,
DST interactions with the two strands are almost identical in strength during the entire unbinding process.
Figure 3. Variations in the MG width along relevant conformations of the LFEP: (a) IMId[50-CGTTGGCC-30]2; (b) DSTd[50-ATTAG-30]2.
5916 Nucleic Acids Research, 2008, Vol. 36, No. 18
Downloaded from https://academic.oup.com/nar/article-abstract/36/18/5910/1072379
by guest
on 19 March 2018
(Table 2). As in the X-ray structure (51), these involve
mostly the nitrogen donors of the ligand and atoms O2
and N3 on the nucleobases. According to the above com-
parisons, our model reproduces the main features revealed
by the X-ray structure.
The complex is mainly stabilized by van der Waals
interactions between DST and the DNA backbone
(Table 2), although electrostatic interactions are also
relevant, specially between the charged amidinium tail
of the drug and the tract d[50-AG-30]2 (data not shown).
As expected from its larger size and contact surface
area, DST makes signiﬁcantly stronger interactions with
the DNA than IMI.
The detachment process starts at the transition state
TS1-2 (Gz=5.4 kcal/mol). Here, the drug is signiﬁcantly
distorted: the amidinium tail points outside the MG ﬂoor,
causing a widening of the MG in the neighboring region,
and the complex gains 10 waters within the ﬁrst hydra-
tion shell (Table 2). Consistently, the average number of
DST–DNA H-bonds decreases, as well as the van der
Waals and the electrostatic interactions. In Min2
(G=4.5 kcal/mol), the drug assumes a conﬁguration
intermediate between that of Min1 and TS1-2. The total
interaction energy is practically the same as in TS1-2, and
a few additional waters enter the hydration shell of ligand
and DNA.
From the very shallow minimum Min2, the detachment
occurs through the highest transition state along the
LFEP, TS2-3 (Gz  18 kcal/mol). Here DST loses con-
tacts with the MG ﬂoor, but it is still bound to the DNA
backbone: the ligand ‘follows’ the strands of the duplex,
while its charged tail remains into the groove (Figure 2).
This loss of (mainly hydrophobic) contacts between the
ligand and the MG walls is mirrored by a signiﬁcant
decrease of van der Waals interactions, while leaving unal-
tered the other nonbonded interactions and the number of
waters within ﬁrst hydration shells (Table 2). As the main
body of DST exits the MG, this latter recovers the same
width as in Min1. The ligand also assumes a conformation
quite similar to that in Min1.
TS2-3 is followed by the intermediate state Min3, in
which the main ligand axis is almost perpendicular to
that of the DNA, and the positive charge on the amidi-
nium tail of DST favorably interacts with the negative
electrostatic potential of AT-rich tracts (8,103). Both
electrostatic and van der Waals interactions slightly
weaken with respect to TS2-3, while the number of
H-bonds between the ligand and the duplex does not
change. Although the solvation free-energy change is sig-
niﬁcant compared to the previous minimum Min2, the
number of waters within the ﬁrst hydration shells of
DST and d[50-CGATTAGC-30]2 is fairly similar to that
found there (Table 2). This might be due to two compen-
sating factors: (i) the narrowing of the MG (Figure 3b),
which causes a decrease of the value of the SASA, con-
trasting the increase of the same due to the dissociation of
the main DST body; (ii) the burying of the charged ami-
dinium tail of DST, which counterbalances the complete
solvation of DST rings and polar hydrogens. In regard to
the structure of the ligand, the rings are almost planar
with respect to each other and Dihe3 also recovers a
value very similar to that found in Min1 (Table S3).
FromMin3 the ligand exits the MG (conﬁguration ‘Out’)
passing through TS3-4 (Gz 7kcal/mol with respect to
Min3 and 17kcal/mol relative to Min1), where it is stabi-
lized by electrostatics interactions with strand #1 (Figures 2
and 3b). In this conformation, both DNA and DST gain a
few water molecules in their hydration shells with respect
to Min3, and the hydration free energy is essentially zero as
compared to the unbound conﬁguration.
As found for IMI, during the whole process the DNA
remains closer to the canonical B-DNA conformation
than to A-DNA, whereas the structure of DST undergoes
signiﬁcant changes (Supplementary Table S3). With
respect to Min1 the RMSD of the duplex remains at
1.5–2 A˚, while its value with respect to ‘Free’ decreases
along the minima from Min1 to Out.
Summarizing, dissociation of DST proceeds in three
steps: (i) the amidinium tail partially rearranges and
breaks its H-bonds with DNA; (ii) DST pyrrol rings
become solvated, while the positively charged tail anchors
the drug to MG; (iii) the ligand tail detaches. The eﬀective
activation free energy is 18 kcal/mol, and the free-energy
barrier for the complete DST detachment (from Min3 to
Out) is almost identical to that found for the reverse path
from Min3 to Min2 (G 7 kcal/mol).
We close this section by reporting our results
for DSTDNA0, in which the ligand is bound in the
MG with a reverse orientation with respect to that in
DSTDNA (see Supplementary Figure S1). Interestingly,
the eﬀective free-energy barrier for dissociation is
16.5 kcal/mol, very similar to the value of 18 kcal/mol
in DSTDNA. Also, the mechanism of detachment is
essentially the same: the aminidium tail of the ligand is
the last group to lose contact with the duplex; there is an
intermediate state in which this group is within the MG,
the rest of the ligand being solvated; from this intermedi-
ate, the free-energy barriers associated with binding and
unbinding are very similar, although their value is lower
than that extracted from the simulations on DSTDNA
(see Supplementary Figure S2).
Choice of the CVs
As for any method based on dimensional reduction, the
free energy extracted from metadynamics may depend
signiﬁcantly on the choice of the CVs. Although this selec-
tion should be driven by chemico-physical intuition, it
is ultimately arbitrary. For this reason, we have tested
the reliability of our ﬁndings on the molecular mecha-
nism by performing two additional simulations with dif-
ferent sets of active variables for each system. Namely, we
have: (i) exchanged the set of active CVs, i.e. dCMs nhb for
IMIDNA and dCMs, nhhp for DSTDNA; (ii) activated all
the three CVs. We are aware that these CVs cannot
be totally uncorrelated; however, such a correlation
can aﬀect in principle every choice of CVs function of
geometric coordinates.
Finally, including additional CVs (internal degrees of
freedom of the drugs, Euler angles, etc.) is in principle
possible, but at the price of somehow loosing, at least
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within the framework of the standard metadynamics
approach used in the present work, a simple (yet accurate)
description of the process.
Notably, the mechanism of dissociation proceeds in the
very same way with all the chosen CVs (see Movies in the
Supplementary Material). In particular, in each simulation
the hydrophilic/charged tail is the last group of the ligand
to lose contact with the MG. This indicates that the sets of
CVs we have used to accelerate the dynamics of dissocia-
tion are able to catch the relevant slow motions associated
with the process. In addition, the activation free energies
calculated as a function of dCMs, nhb for IMIDNA
(11 kcal/mol) and dCMs, nhhp for DSTDNA (22 kcal/
mol) are, within the errors, comparable with those calcu-
lated as a function of the original CVs (see results in the
previous paragraphs). Based on these supplementary tests,
we believe that the main features of IMI and DST disso-
ciation from DNA have been captured by our free-energy
proﬁles in Figures 1 and 2.
DISCUSSION AND CONCLUSIONS
In this work, we have used classical MD-based metady-
namics to characterize the dissociation of anthramycin
[a representative of alkylating agents (57,64)] and DST
[a prototype of sequence-readers based on H-bond match-
ing (22,104)] from their noncovalent complexes with DNA.
The calculated eﬀective free-energy barriers associated
with the removal of DST from DNA do not depend
severely on the orientation of the ligand within the MG.
Indeed, the values are 18 kcal/mol in DSTDNA and
16.5 kcal/mol in DSTDNA0, both in good agreement
with the value of 16.6 kcal/mol extracted within the
Arrhenius theory from stopped-ﬂow experiments (19).
The eﬀective free-energy barrier for IMI detachment
is signiﬁcantly lower, 12 kcal/mol. Although no experi-
mental kinetic data are available for IMI, the value is
consistent with the fact that this ligand has lower
molecular weight, contact surface area and number of
H-bonds donors/acceptors compared to DST. Indeed,
DST needs to disrupt a larger pattern of H-bonds, elec-
trostatic and hydrophobic interactions to detach from
its target DNA than IMI (Table 2). In addition, diﬀer-
ent entropy changes upon dissociation—not speciﬁcally
evaluated here—may contribute to the diﬀerent barrier
heights. In fact, the gain in conﬁgurational entropy upon
dissociation should be larger for DST, due to its enhanced
internal ﬂexibility compared to IMI. However, the number
of waters entering the hydration shells of ligand and DNA
after dissociation is certainly smaller in IMIDNA. These
waters are more ‘structured’ than the bulk ones and con-
tribute to lower the entropy of the solvent.
At the mechanistic level, our calculations highlight
the relevant common features and the striking diﬀerences
in the dissociation by the two ligands. Although the ﬁnd-
ing that for both drugs the hydrophobic interactions
provide the main contribution to DNA aﬃnity was some-
how expected, it is interesting that the hydrophilic tails
of the ligands (Scheme 1) leave the MG at last in both
complexes. Note that this result is independent of
choosing the number of H-bonds or hydrophobic contacts
as an active CV. Concerning the diﬀerences, we found that
only in DSTDNA the dissociation goes through a stable
intermediate (Min3 in Figure 2, Min2 in Supplementary
Figure S2), in which the positively charged amidinium
tail of DST complements the negative electrostatic poten-
tial of the d[ATTA]2 tract. From this minimum, dissocia-
tion and reassociation are equally probable. Such an
intermediate was not detected by stopped-ﬂow experi-
ments (19); however, since this state is trapped between
relatively low barriers (7 kcal/mol in DSTDNA and
only 3 kcal/mol in DSTDNA0) with consequently high
escaping rates, we suggest that it may be present but
it has not been experimentally resolved. Thus, we believe
that not only our study is in accordance with avail-
able measurements, but it also reveals molecular
details of the mechanism not easily accessible to the
experiment.
In contrast to DST, one TS only characterizes the
escaping of IMI from the MG. The lack of stable inter-
mediates is possibly due to the fact that the tail of the
molecule, although polar, is neutral; thus, it is not able
to establish electrostatic interactions with the negative
potential of the MG (tract d[50-TTG-30]2) equally strong
as DST (see Table 2). In addition, the MG locally widens
around the drug allowing for hydration of the whole
region between IMI and one strand. Widening and
enhanced hydration trigger the dissociation of IMI also
in the additional metadynamics simulations performed
with diﬀerent sets of CVs. In contrast, no intermediate
or metastable states featuring the presence of water mole-
cules between the ligand and a single DNA strand were
identiﬁed in DSTDNA or DSTDNA0 (Figure 4). This is
probably due to the stronger intermolecular interactions
this ligand establishes with the duplex with respect to IMI,
which renders less likely insertion and stabilization of
waters between ligand and DNA strands.
Although the duplexes undergo signiﬁcant structural
changes along the dissociation paths, the distortions
remain quite localized in both systems, and the duplexes
always stay closer to B- than A-DNA form, without
featuring overall bending. This is in agreement with the
suggestions proposed by Lavery and Sklenar (92), who
pointed out that variations in local parameters like
roll and tilt do not necessary induces global distortion
in the helix.
In an eﬀort at identifying common features among the
mechanism of dissociation by diﬀerent classes of MG bin-
ders, we compare our results for DST with the available
kinetic data (23) for the dye Hoechst 33258 (HST,
Supplementary Chart S1) (105), which is the prototype
of MG noncovalent binders containing benzimidazole
groups. A kinetic model proposed by Breusegem et al.
(23) invokes the presence of a bound intermediate, struc-
turally diﬀerent from the fully bound complex, and
from which the rates of binding and dissociation
are very similar. This situation is extremely reminiscent
of our ﬁndings for DST: an intermediate featuring
the ligand partially bound to the DNA duplex exists,
for which the free energy barriers for association or dis-
sociation are very similar.
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To the best of our knowledge, the present computa-
tional study provides the ﬁrst molecular-level characteri-
zation of the mechanism of dissociation from DNA by
the representatives of two classes of pharmacologically
relevant MG binders. The agreement between the calcu-
lated and experimentally available barriers for one of
those (DST) conﬁrms the reliability of metadynamics to
estimate free-energy barriers and to obtain mechanistic
insights into the process (47–49,74). Some of the mecha-
nistic aspects appear to be shared with the structurally
diﬀerent noncovalent MG binder, Hoechst 33258 (17),
which is the prototype of MG binders containing benzimi-
dazoles. These similarities suggest the existence of common
mechanisms among diﬀerent non-covalent MG binders.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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